AIDS. 1997 Jan;11(1):F9-13. Unique Identifier : AIDSLINE MED/97264197
OBJECTIVE AND DESIGN: To study the role and development of non-cytotoxic
CD8+ T-cell-mediated suppression of HIV replication in early perinatal
HIV infection in a prospective study of vertically infected infants. CD8
T-cell-mediated HIV suppression was measured several times during the
first year of life and correlated with viral load, cytotoxic T-cell
(CTL) activity, in vitro antibody production (IVAP) and clinical
outcome. METHODS: CD8+ T-cell-mediated HIV suppression was measured by
comparing the amount of p24 antigen produced by endogenously infected
lymphocytes with cultures of the same number of autologous CD4+ T cells
from which CD8+ cells were removed immunomagnetically. CD8 viral
suppressive activity (VSA) was defined as a > or = 50% reduction in p24
antigen in the cultures containing CD8+ cells. RESULTS: CD8+
T-cell-mediated HIV VSA was detected in 11/16 infants in the first year
of life, including six/nine infants studied before 6 months and as early
as 3 weeks of age. Infants who demonstrated CD8 VSA had a lower early
peak and 6-month setpoint' plasma HIV RNA concentration than infants who
lacked CD8 VSA [1.51 versus 4.94 and 0.094 versus 0.639 x 10(6)
copies/ml, respectively, and higher CD4 percentage at 1 year of age.
Survival of infants lacking CD8 VSA (four/six were rapid progressors)
was shorter than for infants who demonstrated CD8 VSA (none out of 10
were rapid progressors). CD8 VSA was present before CTL and before or at
the same time as IVAP in two of two and 11 of 14 infants studied,
respectively. CONCLUSIONS: CD8+ T-cell-mediated VSA can be demonstrated
in a large proportion of HIV-infected infants early in the course of
infection. This non-cytolytic HIV-suppressive immune response appears to
play an important protective role in the early control of perinatal HIV
infection at a time when other immune responses are either absent or
deficient.
*CD8-Positive T-Lymphocytes/IMMUNOLOGY *HIV Infections/IMMUNOLOGY
*HIV-1/IMMUNOLOGY *Virus Replication/IMMUNOLOGY
www.aegis.org